Ovarian tumors metastatic

This digestion, isolation, and storage approach has been successfully applied to a wide range of tumor and normal tissues. Tumor tissues include both primary and metastatic tumors of the more common types, such as colon, lung, and ovarian tumors, melanomas, and sarcomas, and rare tumors, such as schwannoma. Normal cell populations include lung, ovary, colon, heart, liver, kidney, and blood. 

Davidson, B., Berner, A., Nesland, J. M., Risberg, B., Kristensen, G. B., Trope, C. G., and Bryne, M. 2000. Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma Evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions. Hum. Pathol. 37 1081-1087. 

The usual dosage for metastatic testicular tumors is 20 mg/tn intravenously daily for 5 days, once every. 1 weeks for three courses. Metastatic ovarian tumors are treated with SI) mg/m- intravenously once every 3 weeks. Pretreatment hydr-jfion is recommended for both regimens. ... 

MMPs also act as predictors of recurrence or metastatic risk. High preoperative serum levels of MMP-2 or MMP-3 are predictive of recurrence in patients with advanced urotheliai carcinoma. Furthermore, high levels of MMP-2 in ovarian tumor cells can predict tumor recurrence. The expression of certain MMPs is predictive of metastatic risk. For example, expression of MMP-1 is associated with lymph node metastasis in cervical and peritoneal metastasis in gastric cancer. MMP inhibition may be a therapeutic strategy for cancer. ... 

Importantly, other mucinous neoplasms with morphologic intestinal features, the colloid carcinoma of the lungi45 with goblet cells (100%), and a subset of ovarian mucinous carcinomas (64%) are CDX2 positive. The majority of the colloid lung tumors are TTF-1 positive, a feature that allows distinction from metastatic colorectal mucinous carcinoma. Ovarian mucinous carcinomas may be separated from gastrointestinal mucinous carcinomas by virtue of typical immunostaining for CK7 in the ovarian tumors. 

Ronnett BM, Kurman RJ, Shmookler BM, et al. The morphologic spectrum of ovarian metastases of appendiceal adenocarcinomas a clinicopathologic and immunohistochemical analysis of tumors often misinterpreted as primary ovarian tumors or metastatic tumors from other gastrointestinal sites. Am J Surg Pathol. 1997 21 1144-1155. 

Pitman MB, Triratanachat S, Young RH, Oliva E. Hepatocyte paraffin 1 antibody does not distinguish primary ovarian tumors with hepatoid differentiation from metastatic hepatocellular carcinoma. Int J Gynecol Pathol. 2004 23 58-64. 

Charpin C, Bhan AK, Zurawski VRJ, et al. Carcinoembryonic antigen (CEA) and carbohydrate determinant 19-9 (CA 19-9) localization in 121 primary and metastatic ovarian tumors An immunohistochemical study with the use of monoclonal antibodies. Int J Gynecol Pathol. 1982 1 231-245. 

Logani S, Oliva E, Arnell PM, et al. Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma. Mod Pathol. 2005 18 19-25. 

In addition to the sex-cord stromal tumors, a variety of other benign and primary and metastatic malignant ovarian tumors may have a functioning stroma with estrogenic or androgenic production. However, these elevations will remain commonly subclinical. These tumors include mucinous tumors, rarely endometrioid carcinoma, malignant germ cell tumors, and mucinous metastatic carcinomas [37]. 

Confident distinction between primary and metastatic ovarian cancers is not possible because of overlapping findings in imaging. Bilateral, sharply delineated, purely solid or predominantly solid tumors with necrosis strongly favor the diagnosis of a metastatic ovarian tumor, most likely Krukenberg tumors [68]. Contrast uptake aids in the differentiation of solid ovarian metastases from stromal tumors. Stromal tumors typically display a mild and delayed contrast uptake [69]. If metastases are cystic... 

In phase I clinical trials 47 patients, all of whom had previously failed standard treatments for solid tumors, received the drug in the UK, Italy, and Switzerland on three different schedules.123,124 Dose-limiting toxicities have been defined as bone marrow depression and diarrhea. The latter is treatable with loperamide. Signs of biological activity were seen. Notably one patient with metastatic pancreatic cancer showed a partial response (for 4 months) and two further patients, one with metastatic melanoma and one with bronchoalveolar carcinoma, also showed partial responses. In a phase I trial in combination with 5-FU, a partial response in breast cancer was observed.125 Furthermore, a reduction in tumor marker levels was observed in two patients, one with ovarian cancer, and one with colon cancer. Phase II studies have shown partial responses in cisplatin-resistant ovarian and nonsmall-cell lung cancer.126,127 The indications are that the profile of clinical activity is different and complementary to the mononuclear platinum agents. 

They cause substantial DNA damage in tumor cells, preventing tumor growth. Topotecan has been evaluated in metastatic ovarian cancer. Irinotecan is a prodrug that is metabolized to a topoisomerase I inhibitor it has been used in the treatment of colon and... 

---